Fairbanks, AKNCT07143487Now EnrollingIRB Ready

Colon Adenocarcinoma Clinical Trial in Fairbanks, AK

Access cutting-edge colon adenocarcinoma treatment through this clinical trial at a research site in Fairbanks. Study-provided care at no cost to qualified participants.

Sponsored by Alliance for Clinical Trials in Oncology

Quick Self-Assessment

See if you qualify for this Fairbanks location

Preparing your pre-screening questions…

Expert Care in Fairbanks

Access colon adenocarcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related colon adenocarcinoma treatment provided free

Apply for This Fairbanks Location

Check if you qualify for this colon adenocarcinoma clinical trial in Fairbanks, AK

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fairbanks

    Convenient for AK residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fairbanks site if eligible
  4. 4Begin participation

About This Colon Adenocarcinoma Study in Fairbanks

This clinical trial compares patient (proband)-mediated communication to provider-mediated communication for improving genetic testing in first-degree relatives of patients with newly diagnosed colorectal cancer. It is estimated that 30% of cases of colorectal cancer have a genetic basis and about 15% of these patients have a disease-causing (pathogenic) inherited (germline) variant in a cancer susceptibility gene. Most individuals carrying a pathogenic germline variant are unaware of their cancer risk and may not meet guidelines for genetic testing. Identifying pathogenic germline variants or hereditary cancer syndromes in cancer patients has important implications for their at-risk relatives who may not know that they are at high risk for cancer. The burden of communicating this risk to first-degree relatives often falls on the patients, who may lack sufficient knowledge to correctly share and explain their genetic test results. Receiving provider-mediated communication of genetic testing results may be more effective at communicating genetic risk to first-degree relatives than the usual practice of proband-mediated communication.

Sponsor: Alliance for Clinical Trials in Oncology

Who Can Participate

Inclusion Criteria

STEP 1 PROBANDS: Age \>= 18 years
STEP 1 PROBANDS: Patients with a newly diagnosed (within 3 months of registration), primary colorectal adenocarcinoma, stage I to IV
Histologically proven stage I to IV colon or rectal adenocarcinoma (any T or N, M+). Tumors deemed to originate in the colon can extend into/involve the small bowel (e.g., those at the ileocecal valve). Tumors will be regarded as originating in the colon if the entire tumor is in the colon. In the case of rectal involvement, the cancer will be considered a rectal primary
Patients with more than one primary colon adenocarcinoma are eligible
STEP 1 PROBANDS: No patients with stage 0 or in-situ colorectal cancer
STEP 1 PROBANDS: Patients who have had prior malignancies are eligible, including non-invasive cancers
STEP 1 PROBANDS: Patients with synchronous second malignancies are eligible
STEP 1 PROBANDS: Have not received germline testing in the 2 years prior to enrollment or known hereditary colon cancer syndromes
STEP 1 PROBANDS: Patients must have at least 2 living FDRs who meet the eligibility criteria, with whom the patient is willing to share their cancer diagnosis
STEP 1 PROBANDS: In order to complete the mandatory patient-completed measures and view the video and receive genetic education and counseling, participants must be able to speak and read English or Spanish
STEP 1 PROBANDS: No known diagnosis of dementia or cognitive impairment. Persons with impaired decision-making capacity are ineligible as they need to be able to understand genetic test results, its implications for the patient and family, and explain genetic test results to their family members \
No persons with a known psychiatric or documented developmental disorder that affects cognitive or emotional functions to the extent that the capacity for judgment and reason is significantly diminished, such that they cannot participate based on the judgment of the treating physician
STEP 2 PROBANDS: Probands positive for a pathogenic germline variant (PGV) in a cancer susceptibility gene
FDRs: Age \>= 18 years
FDRs: Have not previously received germline genetic testing or known hereditary colon cancer syndromes
FDRs: FDRs must reside within the United States, as genetic testing from LabCorp is only available to United States (U.S.) residents
FDRs: In order to complete the mandatory patient-completed measures, participants must be able to speak and read English or Spanish

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fairbanks?

Yes, this clinical trial (NCT07143487) has an active research site in Fairbanks, AK that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Colon Adenocarcinoma Treatment Options in Fairbanks, AK

If you're searching for colon adenocarcinoma treatment options in Fairbanks, AK, this clinical trial (NCT07143487) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fairbanks research site is actively enrolling participants for this clinical trial. You'll receive care from experienced colon adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all colon adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Fairbanks, AK

See all alzheimers disease clinical trials recruiting in Fairbanks — not just this study.

Browse Alzheimers Disease Trials in Fairbanks

Ready to Join in Fairbanks?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fairbanks, AK